EP0656365A1 — Substituted 2beta-morpholinoandrostane derivatives
Assigned to Akzo Nobel NV · Expires 1995-06-07 · 31y expired
What this patent protects
The invention is related to substituted 2β-morpholino-androstane derivatives, bonded at their 2β-position to the nitrogen of a group of formula I wherein R represents one to four substituents, each one independently selected from (1-4C) alkyl, phenyl and benzyl, or two a…
USPTO Abstract
The invention is related to substituted 2β-morpholino-androstane derivatives, bonded at their 2β-position to the nitrogen of a group of formula I wherein R represents one to four substituents, each one independently selected from (1-4C) alkyl, phenyl and benzyl, or two at the same carbon atom being together -(CH₂) n - wherein n is 2-6; and Y is O or S, or a pharmaceutically acceptable salt thereof. These steroids are very potent intravenous anaesthetics. The compounds have fast onset times and ideal 'sleep duration' vs. 'recovery to full coordination' profiles.
Drugs covered by this patent
- Zurzuvae (ZURANOLONE) · Biogen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.